Four large-scale production facilities, among others, will become operational in 2014. Evonik is completing a world-scale plant for the production of the amino acid MetAMINO (DL-methionine) for animal feed in Singapore. The specialty chemicals company invested more than €500 million in the construction of the new facility, which is scheduled to start producing in the third quarter of 2014 with an annual capacity of 150,000 metric tons. Evonik is also currently ramping up its global annual capacities of the feed amino acid Biolys (source of L-lysine) to almost 500,000 metric tons by 2015.
In China, Evonik will start up new production facilities for isophorone and isophorone diamine in Shanghai in 2014. These crosslinkers are essential components for the production of industrial floors, synthetic leather, and coatings and paints. They are also used in chemical synthesis and in the growth area of high-performance composite materials, which are used, among other applications, for wind power facilities. The total investment volume is over €100 million.
Evonik is also expanding its global production network with construction in Brazil, where a new plant for the production of substances used in the cosmetics and household consumer goods market will open in 2014. Evonik's investment in the mid double-digit million-Euro range will create a production capacity of approx. 50,000 metric tons per year. The company started up a similar plant in China in 2013.
In Germany, a new facility for the production of functionalized polybutadienes is projected to open in the spring of 2014. The investment volume is in the mid double-digit million-Euro range. Evonik distributes functionalized polybutadiene under the name POLYVEST HT. The material is mainly used for sealing compounds in double-glazed windows and for adhesives, for example in the automotive and electronics industry.
Evonik's investment and growth program will comprise over €6 billion in the period from 2012 to 2016. Two thirds are slated for growth investments, while another third will be spent on existing facilities. Evonik aims to achieve sales of around €18 billion and adjusted EBITDA of more than €3 billion in 2018.